PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRATE AND SIMVASTATIN

摘要

Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor simvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 800 and about 29,300. The solid compositions are manufactured without any need of addition of water or aqueous medium. Simvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.